Search Results - "Calimeri, T."

How we treat primary central nervous system lymphoma by Calimeri, T., Steffanoni, S., Gagliardi, F., Chiara, A., Ferreri, A.J.M.

“…Primary diffuse large B-cell (DLBCL) lymphoma of the central nervous system (CNS) (PCNSL) is a new lymphoma entity, recognized by the 2017 WHO classification…”
Get full text

Quantitative muscle mass biomarkers are independent prognosis factors in primary central nervous system lymphoma: The role of L3-skeletal muscle index and temporal muscle thickness by Leone, R., Sferruzza, G., Calimeri, T., Steffanoni, S, Conte, G.M., De Cobelli, F., Falini, A., Ferreri, A.J.M., Anzalone, N.

“…•Low muscle mass is associated with worse survival in primary central nervous system lymphoma.•Muscle mass biomarkers may be useful for prognostic…”
Get full text

A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells by Calimeri, T, Battista, E, Conforti, F, Neri, P, Di Martino, M T, Rossi, M, Foresta, U, Piro, E, Ferrara, F, Amorosi, A, Bahlis, N, Anderson, K C, Munshi, N, Tagliaferri, P, Causa, F, Tassone, P

Get full text

Erratum to ‘How we treat primary central nervous system lymphoma’: [ESMO Open Volume 6, Issue 4, August 2021, 100213] by Calimeri, T., Steffanoni, S., Gagliardi, F., Chiara, A., Ferreri, A.J.M.

Get full text

CONSOLIDATIVE HCT‐ASCT IS SUPERIOR TO NON‐MYELOABLATIVE CHEMO‐IMMUNOTHERAPY IN NEWLY‐DIAGNOSED PCNSL ‐ UPDATED RESULTS OF THE RANDOMIZED PHASE III MATRIX/IELSG43 TRIAL by Illerhaus, G., Ferreri, A., Binder, M., Borchmann, P., Hasenkamp, J., Stilgenbauer, S., Roeth, A., Weber, T., Egerer, G., Ernst, T., Hertenstein, B., Lenz, G., Kobbe, G., Brunnberg, U., Schmidt, C., Kneba, M., Dreyling, M., Möhle, R., Panse, J., Heinicke, T., Schroll, S., Larsen, T. S., Salwender, H., Naumann, R., Hess, G., Thurner, L., Pukrop, T., Keller, U., Blystadt, A. K., Kroschinsky, F. P., Re, F., Pulczynski, E., Orsucci, L., Pospiech, L., Deckert, M., Ponzoni, M., Wendler, J., Valk, E., Calimeri, T., Kasenda, B., Trepel, M., Fricker, H., Gottberg, P., Burger, E., Ihorst, G., Grishina, O., Hader, C., Zucca, E., Finke, J., Schorb, E.

Get full text

SARS‐COV‐2 INFECTION IN 50 PATIENTS WITH PRIMARY CNS LYMPHOMA: PRESENTATION, EFFECTS ON TUMOR TREATMENT AND OUTCOME IN A SERIES OF THE INTERNATIONAL PCNSL COLLABORATIVE GROUP by Ferreri, A. J. M., Steffanoni, S., Calimeri, T., Laurenge, A., Fox, C. P., Soussain, C., Grommes, C., Sassone, M. C., Touat, M., Boot, J., Crosbie, N., Chaganti, S., Dietrich, J., Alencar, A., Itchaki, G., Hoang Xuan, K., Batchelor, T., Cwynarski, K.

Get full text

PROGNOSTIC FACTORS, MANAGEMENT AND OUTCOME OF AN INTERNATIONAL SERIES OF 41 PATIENTS WITH PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL) AND CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT by Ferreri, A. J.M., Tarantino, V., Cabras, G., Ferrara, F., Zinzani, P. L., Arcaini, L., Castellino, A., Tucci, A., Cocito, F., Davies, A., Salvador Chalup, M. M.B, Cwynarski, K., Nogueira, F. L., Petrucci, L., Muzi, C., Onofrillo, D., Ferrario, A., Ramakrishnan, P., Scalzulli, P. R., Tani, M., Tisi, M. C., Papageorgiou, S. G., Calimeri, T., Angelillo, P., Foppoli, M., Dimou, M., Ponzoni, M., Iannitto, E., Vassilakopoulos, T. P.

Get full text

INTRALESIONAL RITUXIMAB SUPPLEMENTED WITH AUTOLOGOUS SERUM IN RELAPSED CD20+ INDOLENT LYMPHOMAS OF THE CONJUNCTIVA: ACTIVITY AND SAFETY RESULTS OF THE “IRIS” TRIAL by Ferreri, A.J., Sassone, M., Miserocchi, E., Govi, S., Cecchetti, C., Corti, M.E., Calimeri, T., Perrone, S., Mappa, S., Ponzoni, M., Modorati, G.

Get full text

CLARITHROMYCIN AS a “REPURPOSING DRUG” AGAINST LYMPHOMAS: SAFETY AND EFFICACY PROFILES IN 55 PATIENTS WITH EXTRANODAL MARGINAL ZONE LYMPHOMA (EMZL) by Ferreri, A.J., Cecchetti, C., Kiesewetter, B., Sassone, M., Calimeri, T., Perrone, S., Ponzoni, M., Raderer, M.

Get full text

Prophylaxis with high‐dose methotrexate significantly reduces CNS dissemination in patients with diffuse large B‐cell lymphoma (DLBCL) and high‐risk CNS‐IPI score by Ferreri, A.J., Calimeri, T., Cecchetti, C., Vignati, A., Sassone, M., Perrone, S., Girlanda, S., Ponzoni, M., Foppoli, M.

Get full text

R‐CHOP PRECEDED BY ENGINEERED TUMOR NECROSIS FACTOR (TNF) IN RELAPSED OR REFRACTORY PRIMARY DIFFUSE LARGE B‐CELL LYMPHOMA OF THE CNS (rPCNSL): FINAL RESULTS OF THE INGRID TRIAL by Ferreri, A. J., Calimeri, T., Conte, G., Ponzoni, M., Fallanca, F., Cattaneo, D., Scarano, E., Flavio, C., Sassone, M., Foppoli, M., Perrone, S., Cecchetti, C., Lopedote, P., Gritti, G., Castellino, C., Verga, L., Olcese, F., Mazza, R., Ciceri, F., Bordignon, C., Anzalone, N., Corti, A.

Get full text

LONG‐TERM EFFICACY AND SAFETY OF LENALIDOMIDE MAINTENANCE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B‐CELL LYMPHOMA WHO ARE NOT ELIGIBLE FOR AUTOLOGOUS TRANSPLANTATION (ASCT) by Ferreri, A.J., Sassone, M.C., Angelillo, P., Zaja, F., Re, A., Spina, M., Di Rocco, A., Fabbri, A., Stelitano, C., Frezzato, M., Rusconi, C., Zambello, R., Arcari, A., Bertoldero, G., De Lorenzo, D., Volpetti, S., Calimeri, T., Perrone, S., Cecchetti, C., Ciceri, F., Ponzoni, M.

Get full text

Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy by Tassone, P, Tagliaferri, P, Rossi, M, Calimeri, T, Bulotta, A, Abbruzzese, A, Caraglia, M, Neri, P

“…Bone disease (BD) is the hall-mark clinical feature of multiple myeloma (MM), accounting up to 60% of patients with bone pain at diagnosis and 60% with a…”
Get more information

P14.55 Quantitative muscle mass biomarkers are independent prognosis factors in primary central nervous system lymphoma: the role of L3-Skeletal Muscle Index and temporal muscle thickness by Leone, R, Sferruzza, G, Calimeri, T, Steffanoni, S, Conte, G, De Cobelli, F, Falini, A, Ferreri, A, Anzalone, N

“…Abstract BACKGROUND Appropriate patient stratification is of paramount importance in patients with primary central nervous system lymphomas (PCNSL) in order to…”
Get full text

Erratum to ‘How we treat primary central nervous system lymphoma’: ESMO Open Volume 6, Issue 4, August 2021, 100213 by Calimeri, T., Steffanoni, S., Gagliardi, F., Chiara, A., Ferreri, A.J.M.

Get full text

High-dose methotrexate (HD-MTX) as CNS prophylaxis significantly improves outcome in patients with high-risk diffuse large B-cell lymphoma (DLBCL) by Calimeri, T., Cecchetti, C., Vignati, A., Sassone, M., Foppoli, M., Scarfò, L., Ponzoni, M., Ferreri, A.

Get full text

Safety and efficacy of clarithromycin monotherapy in patients (pts) with extranodal marginal zone lymphoma (EMZL) by Cecchetti, C., Kiesewetter, B., Sassone, M., Calimeri, T., Scarfò, L., Raderer, M., Ferreri, A.

Get full text

Safety and tolerability of chemotherapy (CT) containing high doses of methotrexate (HD-MTX) and cytarabine (Ara-C) in patients with primary central nervous system lymphoma (PCNSL) and hepatitis B virus (HBV) infection by Calimeri, T., Lopedote, P., Repetto, M., Vignati, A., Sassone, M., Cecchetti, C., Perrone, S., Foppoli, M., Ciboddo, G., Girlanda, S., Peccatori, J., Chiara, A., Memoli, M., Ferreri, A.

Get full text

A multicentre phase II trial addressing lenalidomide (LEN) maintenance in patients with relapsed diffuse large b-cell lymphoma (rDLBCL) who are not eligible for autologous stem cell transplantation (ASCT) by Sassone, M., Zaja, F., Re, A., Spina, M., Di Rocco, A., Fabbri, A., Stelitano, C., Frezzato, M., Rusconi, C., Zambello, R., Calimeri, T., Scarfò, L., Cecchetti, C., Chiozzotto, M., Ponzoni, M., Ferreri, A.

Get full text

A peroxisome proliferator‐activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid‐related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling by Di Martino, Maria T., Arbitrio, Mariamena, Guzzi, Pietro H., Leone, Emanuela, Baudi, Francesco, Piro, Eugenio, Prantera, Tullia, Cucinotto, Iole, Calimeri, Teresa, Rossi, Marco, Veltri, Pierangelo, Cannataro, Mario, Tagliaferri, Pierosandro, Tassone, Pierfrancesco

Get full text